Single Domain Antibodies: Therapeutic Tools for the Future?
In this blog, ProSci will take you through the advantages of single-domain antibodies (sdAbs)—also known as Nanobodies™, VHH antibodies, camelid antibodies—and how these tools can enhance your viral disease research.
The Advantages of Single Domain Antibodies
Conventional antibodies such as monoclonal (mAb) and polyclonal (pAb) antibodies have been at the forefront of biomedical research, use in diagnostic assays therapies against cancer, immune disorders, and infectious diseases. The market for antibodies is growing significantly as the need for these tools is ever-increasing to keep up with the constant battle between diseases and human health.
Disadvantages of Conventional Antibodies
Although conventional antibodies serve as the foundation for highly successful research, diagnostic and therapeutic tools, they do have their disadvantages such as stability over a narrow pH and temperature range and may not be able to access particular active sites on proteins.
These disadvantages might not hinder your research results, but a smaller-sized single domain antibody can increase therapeutic efficacy. A study from the Annals of Medicine, about the challenges in monoclonal antibody-based therapies, pointed out how the current manufacturing and purification processes of monoclonal antibodies cause limitations in the production capacity of therapeutic antibodies, which leads to an increase in cost (1). In a study by Vanlandschoot et al. (2), the advantages of sdAbs were reviewed in relation to their possible therapeutic applications against various viral diseases such as human immunodeficiency virus-1 (HIV-1), influenza A virus, reparatory syncytial virus (RSV), are discussed. View here. Such studies culminated in the first FDA-approved sdAb against von Willebrand factor to treat the blood disease Acquired Thrombotic Thrombocytopenia (3).
How Single Domain Antibodies Can Help
Single domain antibodies from camelid, aim to be the cutting-edge tool for antibody research in cellular mechanisms, cancer, and infectious diseases. Single domain antibodies lack light chains and are smaller and more stable than conventional antibodies yet they possess a fully functional antigen-binding capacity. Due to their size (approximately 15 kDa) and their longer and structurally unique Complementarity Determining Region 3 (CDR3 region), a single domain antibody is adept at reaching otherwise inaccessible unique conformational features on a target that may play a crucial role in the molecular mechanisms of disease.
Conventional antibody vs. Single domain antibody
Features and Benefits of Single Domain Antibodies
Here are ways single domain antibodies can help excel your research:
- Smallest functional antibody unit at ~15kDa; conventional antibody is ~150kDa
- Enhanced tissue penetration, can cross the blood-brain barrier
- Unique binding capacity to small cavities or clefts
- High affinity and specificity
- Highly stable at room temperature and under extreme temperatures and pH
- High solubility, great imaging agents due to rapid clearance in vivo
- Cost-effective, large-scale production
The unique properties of size, stability and solubility for a single domain antibody allow breakthroughs in the field of cancer research, drug development, and therapy. With a variety of ways to use single domain antibodies and the ability to effectively target cancer cells, it’s no surprise that single domain antibodies are on the front lines in the fight against cancer.
Enhance your Research with ProSci
ProSci offers Single Domain Antibody Services from Immunization to Production. Throughout all six phases (from immunization to production), single domain integrity is ensured with various milestones and an unwavering commitment to customer satisfaction. If your application calls for single domain antibodies, purchase ProSci single domain antibodies with confidence.
The ProSci sdAb prototype has a myc-tag for easy detection by an anti-myc antibody.
ProSci provides sdAbs against immune checkpoint targets such as PD-L1, PD-1, LAG3, and TIGIT. Explore the range of ProSci Immune Checkpoint Single Domain Antibodies.
At the onset of the COVID-19 pandemic, ProSci developed antibodies against the S1 and S2 domains as well as trimers of the SARS-CoV-2 virus wildtype and of several Variants of Concern. Explore the full range of SARS-CoV-2 Single Domain Antibodies.
- Samaranayake, H., Wirth, T., Schenkwein, D., Räty, J. K., & Ylä-Herttuala, S. (2009). Challenges in monoclonal antibody-based therapies. In Annals of Medicine (Vol. 41, Issue 5, pp. 322–331). Informa UK Limited. https://doi.org/10.1080/07853890802698842
- Vanlandschoot, P., Stortelers, C., Beirnaert, E., Ibañez, L. I., Schepens, B., Depla, E., & Saelens, X. (2011). Nanobodies®: New ammunition to battle viruses. In Antiviral Research (Vol. 92, Issue 3, pp. 389–407). Elsevier BV. https://doi.org/10.1016/j.antiviral.2011.09.002
- Scully, M., Cataland, S.R., Peyvandi, F., Coppo, P., Knöbl, P., Kremer Hovinga, J.A., Metjian, A., de la Rubia, J., Pavenski, K., Callewaert, F., Biswas, D., De Winter, H. and Zeldin, R.K. for the HERCULES Investigators. (2020). Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. https://pubmed.ncbi.nlm.nih.gov/30625070/
Ask a quote for the following applicationsInstruments 2 Mag reagents 3M kits 77 Elektronika tests A instrumen …14th Apr 2022
Single Domain Antibodies: Therapeutic Tools for the Future?In this blog, ProSci will take you through the advantages of single-domain antibodies (sdAbs)—also k …28th Mar 2022
GelRed and GelGreen– non-toxic nucleic acid stains as an alternative to EtBrEthidium Bromide (EtBr) has become the most used dye for nucleic acid staining due to its low cost …31st Aug 2021